Exclusion criteria
congenital mid-brain malformations, pituitary hormone deficiency, GHD
TUMOURS, HYPOPITUITARISM, SEPTO-OPTIC DYSPLASIA, GHD

Multiple pituitary hormone deficiency (hypopituitarism) with or without additional pituitary hormone supplementationKnown genetic cause of I-GHDOrganic GHD (mid-brain tumours, congenital mid-brain malformations, septo-optic dysplasia; radiotherapy to the total body or brain)Ectopic posterior pituitaryOther indications for GH therapyReceiving GH treatment at any time between the (minimum 6-week) GH discontinuation period prior to retesting and randomisationReceiving prednisolone or dexamethasone at any time during the (minimum 6-week) GH discontinuation periodKnown history of persistent non-compliance with prescribed medication regimensPregnant or lactatingAny malignancyCurrently participating in another Clinical Trial of an Investigational Medicinal Product (CTIMP)